Infectious Disease

Enzolytics, Samsung Biologics partner to develop therapies for HIV, Covid-19

Samsung Biologics and Enzolytics have entered a strategic contract development and manufacturing organization (CDMO) collaboration agreement to develop and produce monoclonal antibody treatments for human immunodeficiency virus (HIV) and Covid-19.

AstraZeneca seeks FDA EUA for antibody cocktail to prevent Covid-19

AstraZeneca has sought Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for its AZD7442 to prevent symptomatic Covid-19.

Australia signs agreement for new Covid-19 drug

Australia has signed an agreement for 300,000 courses of molnupiravir, an antiviral pill that has shown signs of reducing deaths and hospitalisations due to Covid-19.

Trevena reports positive results of TRV027 proof-of-concept trial in Covid-19 patients

Trevena has announced positive results from a proof-of-concept clinical trial during which its new AT1 receptor-selective agonist, TRV027, was found to be well-tolerated in Covid-19 patients who have been hospitalised. 

Pfizer-BioNTech reports positive results for Covid-19 vaccine trail in children aged 5 to 11 years

Pfizer and its partner BioNTech have announced positive topline results from a pivotal trial of their Covid-19 vaccine in children aged 5 to 11 years.

US FDA declines Humanigen’s request for EUA for Covid-19 antibody lenzilumab

The US Food and Drug Administration (FDA) has declined Humanigen’s request for Emergency Use Authorization (EUA) of its antibody lenzilumab to treat newly hospitalised Covid-19 patients. 

AIM submits Pre-IND application to study Ampligen for Covid-19

AIM ImmunoTech has submitted a pre-investigational new drug (Pre-IND) application to the US Food and Drug Administration (FDA) for a study of Ampligen as a potential infusion treatment for post-Covid-19 cognitive dysfunction (PCCD).

India’s Reliance secures DCGI nod to carry out Phase I Covid-19 vaccine trial

The Drugs Controller General of India (DCGI) has given approval to Reliance Life Sciences to conduct a Phase I clinical trial of its Covid-19 vaccine with certain conditions.

Senhwa secures DMC approval to advance Phase II trial of Silmitasertib

Senhwa Biosciences has announced that its oral drug, Silmitasertib, has received positive feedback from an independent Data Monitoring Committee (DMC) in an interim review of Phase II investigator-initiated trial in patients with severe Covid-19.